ATE509931T1 - Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür - Google Patents

Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür

Info

Publication number
ATE509931T1
ATE509931T1 AT08732552T AT08732552T ATE509931T1 AT E509931 T1 ATE509931 T1 AT E509931T1 AT 08732552 T AT08732552 T AT 08732552T AT 08732552 T AT08732552 T AT 08732552T AT E509931 T1 ATE509931 T1 AT E509931T1
Authority
AT
Austria
Prior art keywords
methods
derivatives
azaadamantanester
carbamat
application
Prior art date
Application number
AT08732552T
Other languages
English (en)
Inventor
Michael R Schrimpf
Diana L Nersesian
Kevin B Sippy
Jianguo Ji
Tao Li
Lei Shi
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE509931T1 publication Critical patent/ATE509931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08732552T 2007-03-23 2008-03-20 Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür ATE509931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89674507P 2007-03-23 2007-03-23
PCT/US2008/057641 WO2008118742A1 (en) 2007-03-23 2008-03-20 Azaadamantane ester and carbamate derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE509931T1 true ATE509931T1 (de) 2011-06-15

Family

ID=39788934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08732552T ATE509931T1 (de) 2007-03-23 2008-03-20 Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür

Country Status (9)

Country Link
US (2) US8163916B2 (de)
EP (1) EP2129672B1 (de)
JP (2) JP5566698B2 (de)
CN (2) CN101641355A (de)
AT (1) ATE509931T1 (de)
CA (1) CA2679870A1 (de)
ES (1) ES2363998T3 (de)
MX (1) MX2009010174A (de)
WO (1) WO2008118742A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2010145208A1 (en) * 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
WO2010122178A2 (en) * 2010-05-25 2010-10-28 Symrise Gmbh & Co. Kg Cyclohexyl carbamate compounds as skin and/or hair lightening actives
EP2389922A1 (de) * 2010-05-25 2011-11-30 Symrise AG Cyclohexylcarbamatverbindungen als Anti-ageing-Wirkstoffe
JP5838497B2 (ja) * 2010-05-25 2016-01-06 シムライズ アーゲー 抗セルライト有効成分としてのシクロヘキシルカルバメート化合物
EP2619205B1 (de) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrat eines azaadamantanderivates
US8969562B2 (en) 2013-03-12 2015-03-03 Abbvie, Inc. Azaadamantane formate ester and process for preparing azaadamantane derivatives
TW201617342A (zh) * 2014-07-11 2016-05-16 阿法馬根公司 調節α7活性之啶類
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
EP0329932B1 (de) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln
US5140023A (en) * 1990-04-27 1992-08-18 G. D. Searle & Co. Azatetracycle compounds
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) * 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
JP4616971B2 (ja) * 2000-07-18 2011-01-19 田辺三菱製薬株式会社 1−アザビシクロアルカン化合物およびその医薬用途
WO2008096870A1 (ja) * 2007-02-09 2008-08-14 Astellas Pharma Inc. アザ架橋環化合物

Also Published As

Publication number Publication date
JP2010522201A (ja) 2010-07-01
US20120190704A1 (en) 2012-07-26
US8163916B2 (en) 2012-04-24
CN103145711A (zh) 2013-06-12
ES2363998T3 (es) 2011-08-22
EP2129672B1 (de) 2011-05-18
US20080255178A1 (en) 2008-10-16
WO2008118742A1 (en) 2008-10-02
JP2014205695A (ja) 2014-10-30
CA2679870A1 (en) 2008-10-02
CN101641355A (zh) 2010-02-03
JP5566698B2 (ja) 2014-08-06
EP2129672A1 (de) 2009-12-09
EP2129672A4 (de) 2009-12-09
MX2009010174A (es) 2009-10-12
HK1133642A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
EP2129672A4 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
JOP20180102B1 (ar) مركب صيدلاني
MA32508B1 (fr) Composes organiques
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
NO20084334L (no) Farmasoytiske sammensetninger
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
NI201001033A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201170832A1 (ru) Пуриновые соединения
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
EP2557919A4 (de) Stabilisierte statinformulierungen
CO6361894A2 (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties